Identification of druggable targets for radiation mitigation using a small interfering RNA screening assay

Radiation Research

Volumn 178, Issue 3, 2012, Pages 150-159

  Zellefrow, Crystal D ^a,b   Sharlow, Elizabeth R ^a,b,c   Epperly, Michael W ^a   Reese, Celeste E ^a   Shun, Tongying ^a   Lira, Ana ^c   Greenberger, Joel S ^a   Lazo, John S ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA;

ACUTE RADIATION SYNDROME; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL POPULATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE IDENTIFICATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IONIZING RADIATION; LD 50; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; STEM CELL; WHOLE BODY RADIATION;

ANIMALS; CELL LINE, TUMOR; CHROMONES; ENZYME INHIBITORS; FEMALE; HEMATOPOIESIS; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; RADIATION TOLERANCE; RADIATION-PROTECTIVE AGENTS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION; WHOLE-BODY IRRADIATION;

MUS;

EID: 84866324698     PISSN: 00337587     EISSN: 19385404     Source Type: Journal    
DOI: 10.1667/RR2810.1     Document Type: Article

References (31)

1. Hall EJ, Giaccia A. Radiobiology for the radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
2. Epperly MW, Franicola D, Shields D, Rwigema JC, Stone B, Zhang X, et al. Screening of antimicrobial agents for in vitro radiation protection and mitigation capacity, including those used in supportive care regimens for bone marrow transplant recipients. In Vivo 2010; 24:9-19.
3. Citrin D, Cotrim AP, Hyodo F, Baum BJ, Krishna MC, Mitchell JB. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010; 15:360-71.
4. Moulder JE, Cohen EP, Fish BL. Captopril and losartan for mitigation of renal injury caused by single-dose total-body irradiation. Radiat Res 2011; 175:29-36.
5. Kim H, Bernard ME, Flickinger J, Epperly MW, Wang H, Dixon TM. The autophagy-inducing drug carbamazepine is a radiation protector and mitigator. Intl J Radiat Biol 2011; 87:1052-60.
6. Johnson SM, Torrice CD, Bell JF, Monahan KB, Jiang Q, Wang Y, et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 2010; 120:2528-36.
7. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1:727-30. (Pubitemid 37361545)
8. Jiang J, McDonald PR, Dixon TM, Franicola D, Zhang X, Nie S. et al. Synthetic protection short interfering RNA screen reveals glyburide as a novel radioprotector. Radiat Res 2009; 172:414-22.
9. Kim K, Pollard JM, Norris AJ, McDonald JT, Sun Y, Micewicz E, et al. High-throughput screening identifies two classes of antibiotics as radioprotectors: tetracyclines and fluoroquinolones. Clin Cancer Res 2009; 15:7238-45.
10. Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, Pollack IF. Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. Neurosurg Focus 2010; 28:E4.
11. Kitchens CA, McDonald PR, Shun TY, Pollack IF, Lazo JS. Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. J Pharmacol Exptl Ther 2011; 339:851-8.
12. Rwigema JC, Beck B, Wang W, Doemling A, Epperly MW, Shields D, Goff JP, Franicola D, et al. Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators. Intl J Rad Oncol 2011; 80:860-8.
13. Thaker NG, Zhang F, McDonald PR, Shun TY, Lewen MD, Pollack IF, et al. Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol 2009; 76:1246-55.
14. Gokhale A, Rwigema JC, Epperly MW, Glowacki J, Wang H, Wipf P, et al. Small molecule GS-nitroxide ameliorates ionizing irradiation-induced delay in bone wound healing in a novel murine model. In Vivo 2010; 24:377-85.
15. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28:1075-83.
16. Vivanco I, Sawyers LC. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002; 2:489-501. (Pubitemid 37328931)
17. Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, et al. Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther 2007; 6:789-801. (Pubitemid 46554549)
18. Thaker NG, McDonald PR, Zhang F, Kitchens CA, Shun TY, Pollack IF, et al. Designing, optimizing, and implementing highthroughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods 2010; 185:204-12.
19. Sarthy AV, Morgan-Lappe SE, Zakula D, Vernetti L, Schurdak M, Packer JC, et al. Surviving depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 2007; 6:269-76. (Pubitemid 46206691)
20. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7:591-600. (Pubitemid 40796982)
21. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007; 446: 815-9. (Pubitemid 46582032)
22. Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, et al. Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. Mol Cell Biol 2006; 26:9377-86. (Pubitemid 44904431)
23. Berns K, Hijmans EM, Mullenders J, Brummelkamp TR, Velds A, Heimerikx M et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428:431-7. (Pubitemid 38419689)
24. Zhang B, Gu X, Uppalapati U, Ashwell MA, Leggett DS, Highcontent fluorescent-based assay for screening activators of DNA damage checkpoint pathways. J Biomol Screen 2008; 13: 538-43. (Pubitemid 351905076)
25. Kaelin WG, The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5:689-98.
26. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001; 15:2177-96. (Pubitemid 32843830)
27. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer association. Nature 2003; 421:486-8.
28. Song L, Li J, Ye J, Yu G, Ding J, Zhang D, et al. p85alpha acts as a novel signal transducer for mediation of cellular apoptotic response to UV radiation. Mol Cell Biol 2007; 27:2713-31. (Pubitemid 46581360)
29. Song L, Gao M, Dong W, Hu M, Li J, Shi X, et al. p85a mediates p53 K370 acetylation by p300 and regulates its promoter-specific transactivity in the cellular UVB response. Oncogene 2011; 30:1360-71.
30. Choi JA, Park MT, Kang CM, Um HD, Bae S, Lee KH, et al. Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. Oncogene 2004; 23:9-20. (Pubitemid 38142235)
31. Carbott DE, Duan L, Davis MA. Phosphoinositol 3 kinase inhibitor, LY294002 increases bcl-2 protein and inhibits okadaic acid-induced apoptosis in Bcl-2 expressing renal epithelial cells. Apoptosis 2002; 7:69-76. (Pubitemid 34145393)